Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CV301 + Anti-PD-1 in NSCLC
NCT02840994Phase 1Completed
- Sponsor
- Bavarian Nordic
- Start
- Dec 2016
- Primary completion
- Jan 2020
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of CV301 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Bavarian Nordic. Primary endpoint: Safety and tolerability of CV301 alone and in combination determined by incidence of dose-limiting toxicities (DLTs). Started Dec 2016; status: completed.
02
Drugs
CV301
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02840994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02840994.